ArticleBritish journal of cancer2026
Deconvolution of haematological cancer methylation patterns reveals a predominantly non-disease related proliferation signal and uncovers true disease associated methylation changes.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCancers are associated with extensive reorganisation of epigenetic patterns, making identification of DNA methylation changes responsible for driving cancer development challenging. Here, we present a novel approach, integrative methylation mapping, which overcomes this, enabling identification of functionally relevant methylation-regulated genes in cancer.
methodsComparison of genome-wide DNA methylation across multiple B-lymphocyte derived malignant/normal samples (total n = 995), enabled delineation of changes related to normal or cancer cell functions. Chromatin structure profiling (SeSAMe) analysis delineated different properties characterising the different categories of methylation change and lentiviral based re-expression enabled functional assessment of identified candidate genes.
resultsThis analysis determined that only 2-3% of DNA methylation changes in B-cell cancers are disease driven, with the overwhelming majority driven by normal processes, predominantly proliferation. Methylation changes associated with specific cancer or normal cell processes exhibited unique patterns of sequence context, chromatin structure and associated transcription factors. Furthermore, the low level of true disease-specific changes simplifies identification of functionally relevant methylation changes, illustrated here by identification and functional confirmation of SLC22A15 as a tumour suppressor in acute lymphoblastic leukaemia.
conclusionsThis approach leads to a clearer understanding of the role of altered DNA methylation in haematological cancer, facilitates identification of cancer-relevant DNA methylation targeted genes and novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.